Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Review, H2 2020 - ResearchAndMarkets.com October 08, 2020 12:24 PM Eastern Daylight Time ...

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and ...

The Food and Drug Administration (FDA) has approved Gammagard Liquid ® (immune globulin infusion 10% [human]) to improve neuromuscular disability and impairment in adult patients with chronic ...

CSL Behring announced that the Food and Drug Administration (FDA) has approved Hizentra (immune globulin subcutaneous [human] 20% liquid) for the treatment of chronic inflammatory demyelinating ...

Patients with diagnosed chronic inflammatory demyelinating polyneuropathy (CIDP) treated with efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) saw a 61% reduction in the risk of relapse ...

The FDA has approved Takeda Pharmaceutical’s Hyqvia, coformulated with Halozyme's Enhanze drug delivery technology, to treat chronic inflammatory demyelinating polyneuropathy in adults.According ...

Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.A ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired neurological disorder with heterogeneous presentation. It is a peripheral nerve system immune-mediated condition which ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) affects the peripheral nerves. Tests to diagnose this condition include nerve conduction studies, electromyography, and sometimes an MRI.

Chronic Inflammatory Demyelinating Polyneuropathy Companies such as Takeda, Sanofi, Johnson & Johnson Services, Immunovant, UCB S.A., GeNeuro, Nanjing IASO Biotherapeutics, Bioasis Technologies ...